Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07190469 · ClinicalTrials.gov registry record · Phase 1
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Cancer (TNBC) and Advanced Solid Tumors Cancer, sponsored by ProteinQure.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT07190469: Recruiting Phase 1 study of Triple Negative Breast Cancer (TNBC) and Advanced Solid Tumors Cancer, sponsored by ProteinQure.
NCT07190469 is a Phase 1 study of Triple Negative Breast Cancer (TNBC) and Advanced Solid Tumors Cancer that is actively recruiting participants, run by ProteinQure. The registered enrollment target is 80 participants, below the 153-participant average among 14 other Triple Negative Breast Cancer (TNBC) trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07190469, a Phase 1 study of Triple Negative Breast Cancer (TNBC) and Advanced Solid Tumors Cancer, is actively recruiting participants, sponsored by ProteinQure.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Primary Outcome
The incidence and severity of Adverse Events (AEs) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) to assess safety and tolerability.
Conditions Studied
Interventions
- DRUG PQ203
Study Locations (4)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Utah
- START Mountain Region - West Valley City
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT07190469 shows while recruiting
NCT07190469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 153-participant average among 14 other Triple Negative Breast Cancer (TNBC) trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with Triple Negative Breast Cancer (TNBC) appearing as the primary indexed condition, and to 1 intervention - of which PQ203 is the first listed.
NCT07190469 reports a single indexed study location in Texas, Utah, Ontario.
Frequently Asked Questions
What is clinical trial NCT07190469 about?
NCT07190469 is a clinical study titled "PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer". The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
What is the current status of trial NCT07190469?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-09-16. Estimated completion is 2029-02.
What conditions does trial NCT07190469 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT07190469?
The interventions under investigation include: PQ203 (DRUG).
Who is sponsoring clinical trial NCT07190469?
This trial is sponsored by ProteinQure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07190469 being conducted?
This trial has 4 study locations across Texas, Utah, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer (TNBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07190469's enrollment target sits among peer trials
80 11th of 14 higher than 4 of 14 other Triple Negative Breast Cancer (TNBC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer (TNBC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RECRUITING · Phase 1
-
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI